Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group.
observational
real-life
soft tissue sarcoma
trabectedin
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Mar 2021
02 Mar 2021
Historique:
received:
04
02
2021
revised:
24
02
2021
accepted:
25
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
The Italian Sarcoma Group performed this retrospective analysis of patients with advanced soft tissue sarcoma, pretreated with ≥1 anthracycline-based treatment, and treated with trabectedin every three weeks. Primary endpoint was to describe real-life use of trabectedin across Italy. Secondary endpoints included objective response rate (ORR) and safety. Overall, 512 patients from 20 Italian centers were evaluated. Leiomyosarcoma (37.7%)/liposarcoma (30.3%) were the most prevalent histological types (abbreviated as L-sarcoma). Patients received a median of four trabectedin cycles (range: 1-40), mostly as a second-line treatment (~60% of patients). The ORR was 13.7% superior (
Identifiants
pubmed: 33801399
pii: cancers13051053
doi: 10.3390/cancers13051053
pmc: PMC7958606
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02793050']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : PharmaMar
ID : 00
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Histopathology. 2014 Jan;64(1):38-52
pubmed: 24118009
Cancer. 2012 Nov 1;118(21):5339-48
pubmed: 22517534
Cancer Chemother Pharmacol. 2016 Apr;77(4):663-71
pubmed: 26666647
J Clin Oncol. 2016 Mar 10;34(8):786-93
pubmed: 26371143
Drug Des Devel Ther. 2015 Oct 27;9:5785-91
pubmed: 26604682
Ann Oncol. 2013 Jun;24(6):1703-9
pubmed: 23385197
J Clin Oncol. 2009 Sep 1;27(25):4188-96
pubmed: 19652065
Future Oncol. 2013 Dec;9(12 Suppl):5-10
pubmed: 24195524
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269
pubmed: 30285214
J Clin Oncol. 1999 Jan;17(1):150-7
pubmed: 10458228
Invest New Drugs. 2012 Jun;30(3):1193-202
pubmed: 21484250
BMC Cancer. 2013 Feb 06;13:64
pubmed: 23388156
Case Rep Oncol. 2020 Feb 11;13(1):113-119
pubmed: 32231532
Anticancer Drugs. 2017 Nov;28(10):1157-1165
pubmed: 28926423
Anticancer Drugs. 2015 Jul;26(6):678-81
pubmed: 25763543
Lancet Oncol. 2015 Mar;16(3):312-9
pubmed: 25680558
Eur J Cancer. 2015 Jul;51(10):1312-20
pubmed: 25912752
Lancet Oncol. 2015 Apr;16(4):406-16
pubmed: 25795406
Br J Cancer. 2013 Oct 1;109(7):1717-24
pubmed: 24022187
Cancer. 2019 Aug 1;125(15):2610-2620
pubmed: 31173362
Mol Cancer Ther. 2010 Aug;9(8):2157-63
pubmed: 20647340
Eur J Cancer. 2014 Mar;50(4):679-89
pubmed: 24295638
Eur J Cancer. 2015 Apr;51(6):742-50
pubmed: 25727882
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336